Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

212.04USD
23 Aug 2019
Change (% chg)

$-4.63 (-2.14%)
Prev Close
$216.67
Open
$216.67
Day's High
$217.37
Day's Low
$210.88
Volume
288,078
Avg. Vol
329,979
52-wk High
$226.31
52-wk Low
$136.47

Latest Key Developments (Source: Significant Developments)

Edwards Lifesciences Reports Qtrly EPS Of $1.14
Tuesday, 23 Jul 2019 04:15pm EDT 

July 23 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES - QTRLY EPS $1.14; QTRLY ADJUSTED EPS $1.38; QTRLY SALES UP 15% TO $1.1 BILLION.EDWARDS LIFESCIENCES – EXPECTS Q3 FDA APPROVAL OF THE SAPIEN 3 VALVE FOR PATIENTS WITH LOW SURGICAL RISK.EDWARDS LIFESCIENCES – FOR 2019, EXPECTS TOTAL SALES BETWEEN $4.0 BILLION AND $4.3 BILLION.EDWARDS LIFESCIENCES – RAISED FY 2019 ADJUSTED EPS GUIDANCE TO $5.20 TO $5.40 FROM $5.10 TO $5.35.FY2019 EARNINGS PER SHARE VIEW $5.30, REVENUE VIEW $4.16 BILLION -- REFINITIV IBES DATA.EDWARDS LIFESCIENCES SEES Q3 TOTAL SALES BETWEEN $1.02 BILLION & $1.06 BILLION, SEES Q3 ADJUSTED EPS $1.13 TO $1.23.EDWARDS LIFESCIENCES - DURING QUARTER, RECORDED $46 MILLION CHARGE PRIMARILY COMPRISED OF INVENTORY, RELATED TO TRANSCATHETER AORTIC VALVE PORTFOLIO DECISIONS.EDWARDS LIFESCIENCES - QTRLY TRANSCATHETER AORTIC VALVE REPLACEMENT SALES OF $678 MILLION, UP 16%.Q2 EARNINGS PER SHARE VIEW $1.33, REVENUE VIEW $1.04 BILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE VIEW $1.25, REVENUE VIEW $1.02 BILLION -- REFINITIV IBES DATA.  Full Article

FDA Says Edwards Lifesciences Recalls The IntraClude Intra-Aortic Occlusion Device Due To Risk Of Balloon Rupture
Monday, 1 Jul 2019 04:03pm EDT 

July 1 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS EDWARDS LIFESCIENCES RECALLS THE INTRACLUDE INTRA-AORTIC OCCLUSION DEVICE DUE TO RISK OF BALLOON RUPTURE.U.S. FDA SAYS EDWARDS LIFESCIENCES RECALLED 757 INTRACLUDE INTRA-AORTIC OCCLUSION DEVICES IN U.S; EDWARDS LIFESCIENCES INITIATED RECALL ON MAY 14.U.S. FDA SAYS HAS IDENTIFIED EDWARDS LIFESCIENCES' RECALL OF THE INTRACLUDE INTRA-AORTIC OCCLUSION DEVICE AS A CLASS I RECALL.U.S. FDA - EDWARDS LIFESCIENCES GOT 22 COMPLAINTS ON BALLOON RUPTURE/PUNCTURE FOR INTRACLUDE INTRA-AORTIC OCCLUSION DEVICE; 3 DEATHS HAVE BEEN REPORTED.  Full Article

Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corp
Monday, 3 Jun 2019 04:15pm EDT 

June 3 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES RECOMMENDS STOCKHOLDERS REJECT "MINI-TENDER OFFER" BY TRC CAPITAL CORPORATION.EDWARDS LIFESCIENCES CORP - RECEIVED NOTICE OF AN UNSOLICITED "MINI-TENDER OFFER" BY TRC CAPITAL CORPORATION TO PURCHASE UP TO 1 MILLION SHARES.EDWARDS LIFESCIENCES CORP - TRC CAPITAL'S OFFER PRICE IS FIXED AT $162.38 PER SHARE.  Full Article

Edwards Lifesciences Q1 Earnings Per Share $1.18
Tuesday, 23 Apr 2019 04:15pm EDT 

April 23 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $1.32.Q1 EARNINGS PER SHARE $1.18.Q1 SALES $993 MILLION VERSUS REFINITIV IBES ESTIMATE OF $989.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.22 -- REFINITIV IBES DATA.2019 SALES GUIDANCE FOR EDWARDS OF $3.9 TO $4.3 BILLION REMAINS UNCHANGED.RAISED ITS FULL YEAR 2019 ADJUSTED EARNINGS PER SHARE GUIDANCE TO $5.10 TO $5.35.2019 ADJUSTED EPS GUIDANCE RAISED TO $5.10 TO $5.35.2019 SALES GUIDANCE FOR EDWARDS OF $3.9 TO $4.3 BILLION REMAINS UNCHANGED.FOR Q2 2019, COMPANY PROJECTS TOTAL SALES TO BE BETWEEN $1.02 BILLION AND $1.08 BILLION.FOR Q2 2019, COMPANY PROJECTS ADJUSTED EPS OF $1.27 TO $1.37. ADJUSTED EPS OF $1.27 TO $1.37..Q2 EARNINGS PER SHARE VIEW $1.33, REVENUE VIEW $1.04 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $5.21, REVENUE VIEW $4.14 BILLION -- REFINITIV IBES DATA.2019 SALES GUIDANCE FOR EDWARDS OF $3.9 BILLION TO $4.3 BILLION REMAINS UNCHANGED.EDWARDS LIFESCIENCES - FOR QUARTER, REPORTED TAVR SALES OF $598 MILLION, 8 PERCENT GROWTH RATE OVER Q1 LAST YEAR, OR 10 PERCENT ON AN UNDERLYING BASIS.EDWARDS LIFESCIENCES - DURING QUARTER, RECORDED A $24 MILLION CHARGE RELATED TO PREVIOUSLY ANNOUNCED ACQUISITION OF STRATEGIC TRANSCATHETER TECHNOLOGY.  Full Article

Edwards Lifesciences Says CEO's FY18 Compensation Was $10.3 Mln
Wednesday, 27 Mar 2019 05:18pm EDT 

March 27 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2018 TOTAL COMPENSATION WAS $10.3 MILLION VERSUS $10.8 MILLION IN FY 2017 - SEC FILING.EDWARDS LIFESCIENCES CORP SAYS ESTIMATE RATIO OF CEO’S TOTAL COMPENSATION FOR 2018 TO MEDIAN OF TOTAL COMPENSATION OF ALL OF EMPLOYEES TO BE 206 TO 1.  Full Article

Edwards Lifesciences Invests $35 Mln In An Exclusive Right To Acquire Corvia Medical Inc
Monday, 11 Mar 2019 08:30am EDT 

March 11 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES ANNOUNCES STRATEGIC INVESTMENTS.EDWARDS LIFESCIENCES CORP - EDWARDS HAS INVESTED $35 MILLION IN AN EXCLUSIVE RIGHT TO ACQUIRE CORVIA MEDICAL, INC..EDWARDS LIFESCIENCES CORP - EDWARDS HAS ALSO ACQUIRED CERTAIN ASSETS OF MITRALIGN, INC.,.EDWARDS LIFESCIENCES CORP - ADDITIONAL TERMS OF THESE TRANSACTIONS REMAIN CONFIDENTIAL.EDWARDS LIFESCIENCES CORP - ANNOUNCEMENT IS NOT EXPECTED TO IMPACT EDWARDS' 2019 FINANCIAL GUIDANCE..  Full Article

Edwards Comments On U.S. Court Decision
Tuesday, 11 Dec 2018 06:45pm EST 

Dec 11 (Reuters) - Edwards Lifesciences Corp ::EDWARDS COMMENTS ON U.S. COURT DECISION.COMMENTED TODAY ON A FEDERAL JURY'S DECISIONS IN PATENT LITIGATION BETWEEN EDWARDS AND BOSTON SCIENTIFIC.EDWARDS LIFESCIENCES-DOES NOT EXPECT TO PAY JURY AWARD SINCE U.S. PATENT AND TRADEMARK OFFICE DETERMINED ASSERTED CLAIMS OF '608 PATENT WERE INVALID.  Full Article

Edwards Lifesciences Reports Q2 Earnings Of $1.32/Share
Thursday, 26 Jul 2018 04:15pm EDT 

July 26 (Reuters) - Edwards Lifesciences Corp ::QUARTERLY EARNINGS PER SHARE $1.32.QUARTERLY ADJUSTED EARNINGS PER SHARE $1.24.QUARTERLY SALES $944 MILLION, UP 12 PERCENT.QUARTERLY TOTAL ADJUSTED SALES $972 MILLION, UP 10 PERCENT.SAYS 2018 ADJUSTED. EARNINGS PER SHARE OUTLOOK RAISED TO $4.60-$4.75 FROM $4.50-$4.70.SAYS CONFIDENT IN ACHIEVING HIGHER END OF 2018 SALES OUTLOOK RANGE OF $3.5 BILLION-$3.9 BILLION.SEES Q3 TOTAL SALES OF $900 MILLION-$950 MILLION.SEES Q3 ADJUSTED EARNINGS PER SHARE OF $0.93-$1.03.QUARTERLY TRANSCATHETER HEART VALVE THERAPY SALES OF $585 MILLION, UP 20 PERCENT.Q2 EARNINGS PER SHARE VIEW $1.14, REVENUE VIEW $969.0 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $4.63, REVENUE VIEW $3.84 BILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $1.08, REVENUE VIEW $934.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Edwards Lifesciences Says Entered Into Credit Agreement To Establish Multi-Currency Unsecured Revolving Credit Facility - SEC Filing
Monday, 30 Apr 2018 05:25pm EDT 

April 30 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES SAYS ENTERED INTO CREDIT AGREEMENT TO ESTABLISH NEW 5-YEAR $750 MILLION MULTI-CURRENCY UNSECURED REVOLVING CREDIT FACILITY - SEC FILING.EDWARDS LIFESCIENCES SAYS NEW AGREEMENT TO REPLACE THE EXISTING $750 MILLION UNSECURED REVOLVING CREDIT FACILITY UNDER THE 2014 CREDIT AGREEMENT.EDWARDS LIFESCIENCES - MAY INCREASE AMOUNT OF REVOLVING CREDIT FACILITY UNDER CREDIT AGREEMENT BY UP TO ADDITIONAL $250 MILLION IN THE AGGREGATE.  Full Article

Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences
Monday, 16 Apr 2018 04:45pm EDT 

April 16 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES.BOSTON SCIENTIFIC CORP - SUCCESSFULLY OPPOSED EDWARDS LIFESCIENCES' EUROPEAN PATENT EP 2,399,550, RESULTING IN REVOCATION OF PATENT.BOSTON SCIENTIFIC - GERMAN COURT OF APPEAL TO HAVE HEARING IN MAY, JUNE THIS YEAR ABOUT CO'S PATENTS '254, '766 THAT EDWARDS WAS FOUND TO INFRINGE.  Full Article

FDA pegs Edwards Lifesciences Sapien delivery system recall as severest

The U.S. health regulator on Thursday categorized the recall of Edwards Lifesciences Corp's Sapien 3 Ultra delivery system as extremely serious, highlighting health risks associated with its use, but the products will remain on the market.